Increased innate immune responses in adolescents with obesity and its relation to subclinical cardiovascular measures: An exploratory study.
Disease
Health sciences
Immunology
Pathophysiology
Risk factor
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
17 May 2024
17 May 2024
Historique:
received:
13
11
2023
revised:
16
02
2024
accepted:
15
04
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
14
5
2024
Statut:
epublish
Résumé
Cardiometabolic risk accrues across the life course and childhood and adolescence are key periods for effective prevention. Obesity is associated with inflammation in adults, but pediatric data are scarce. In a cross-sectional and longitudinal study, we investigated immune cell composition and activation in 31 adolescents with obesity (41.9% male, BMIz>2.5, 14.4 years) and 22 controls with healthy weight (45.1% male, -1.5<BMIz<1.5, 14 years). In those with obesity, we assessed the impact of weight change and correlations between immune profiles and subclinical cardiovascular phenotypes at a 5-year follow-up. Compared to controls, those with obesity had increased monocyte activation and cytokine production upon stimulation. Monocyte transcriptomics demonstrated upregulated inflammatory pathways and downregulated antiviral responses. Weight change was not associated with changes in inflammation. Baseline inflammation correlated with cardiovascular measures at follow-up. Children with obesity have increased inflammation, which associates with worse subsequent subclinical cardiovascular measures. Adjunctive anti-inflammatory interventions may be needed to reverse adverse subclinical cardiovascular phenotypes.
Identifiants
pubmed: 38741712
doi: 10.1016/j.isci.2024.109762
pii: S2589-0042(24)00984-2
pmc: PMC11089376
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109762Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
M.G.N. is scientific founder of TTxD and Lemba Therapeutics.